Professional Documents
Culture Documents
Life Sciences and Medicine - Round 1 - Editing Test
Life Sciences and Medicine - Round 1 - Editing Test
Life Sciences and Medicine - Round 1 - Editing Test
Editing Test
Brief
● In this test, you will find extracts from research manuscripts.The test has been
designed to gauge editorial sensibilities, language and grammar, mechanics and style,
subject-matter expertise, referencing skills, logic and comprehension, and attention to
detail.
● The passages contain errors in grammar, punctuation, and spelling, and most of the
sentences are not written in native English. You need to edit the passage by correcting
these errors.
● Note that we do not share detailed test results/feedback in order to keep the test
reusable.
Instructions
● Edit any two passages that are most relevant to your educational qualifications and
background. Please note that if you are attempting the biomedical passage, you will need to
attempt both the sub passages along with either the Neuroscience or Plants and Animal
science passage.
● Use Track Changes to edit the content (press Ctrl + Shift + E or select Track
Changes from the Review tab). Make inline changes and do not strike off complete
sentences and rewrite them separately.
● Use comments to communicate with the author. Comments can be inserted by
selecting the relevant text and pressing Alt + I + M or New Comment from the Review
tab.
● Use either American or British English, but not both.
● You may use a dictionary and/or thesaurus.
● Make a note of the time taken to complete editing each passage.
● Rename the file by adding your full name before the filename (e.g., “John
Doe_Editing Test”).
Below is a sample edit to help you understand the kinds of edits you are expected to make.
Test Passages
Biomedical
Part 1
Whether the incidence of coronary heart disease (CHD) is related to the decrease in total
antioxidant capacity (TAC) has not been completely clarified yet. We have assessed TAC of
blood serum in a group of 163 males with CHD aged between 34.8–77.0 years and in 163
age-matched peer individuals without CHD. Two spectrophotometries were applied to assess
TAC; ferric reducing ability of serum (TAC-FRAS) and 2.2-diphenyl-1-picryl-hydrazyle
(TAC-DPPH) tests. In CHD group, multivariate analysis reveal that uric acid (UA),
triglycerides, and systolic blood pressure contributed independently to the TAC-FRAS
variance. TAC-DPPH was favorably predicted by UA concentration, but negatively so by
current smoking and glucose levels. In males without CHD, UA was the only independent
determinant of both TAC-FRAS and TAC-DPPH. Presence of CHD was not independent
predictor of TAC—observed between-group differences (higher TAC in CHD patients)
disappeared after adjustment for other confounders. We conclude that UA is the main
determinant of TAC of blood serum in males. TAC is also not directly influenced by age or
CHD but is related to several indices of overweight/obesity and lab measures of metabolic
syndrome, especially in CHD patients.
Part 2
Metformin is one of the most widely prescribed antidiabetics for the type 2 diabetes. The
critical role of metformin against tumorigenesis has recently been implicated, although
several studies also reported the lack of anticancer property of the antidiabetics. Given the
controversies regarding the potential role of metformin against tumour progression, the effect
of metformin against breast, cervical and ovarian tumour cell lines was examined followed by
in vivo a ssessment of metformin on tumour growth using xenograft breast cancer models.
Significant inhibitory impact of metformin was found on MCF-7, HeLa, and SKOV-3 cells,
suggesting an antiproliferative property of metformin against breast, cervical and ovarian
tumour cells, respectively, with the breast tumour cells, MCF-7, being the most
responsiveness. in vivo assessment was carried out subsequently, where mice with breast
tumours were treated with metformin (20 mg/kg bo. wt.) or sterile PBS solution for 15
consecutive days. No inhibition of breast tumour progression was detected in these rats.
However, tumour necrosis was significantly increased in the metformin-treated group,
accompanied by decreased capillary formation within the tumours. Thus, despite the lack of
short-term benefit of metformin against tumour progression, a preventive role of metformin
against breast cancer was implicated in this study, which is at partially attributable to the
attenuation of tumour angiogenesis.
Part 2 Source: Attenuating Tumour Angiogenesis: A Preventive Role of Metformin against Breast
Cancer by S. Gao, J. Jiang, P. Li, et al., used under C
C-BY
Confidential
Neuroscience
The argan forests (Argania spinosa (L.) Skeels) extend over 8700 square kilometers [1]. For
centuries, argan tree has shaped the socioeconomic life of the southwestern Morocco,
becoming a flagship species for the region and for the country [2]. This space has been
declared by UNESCO’s Man and the Biosphere (MAB) Programme as biosphere reserve in
1998. The argan tree is the major tree species of Macaronesian formations in a climate
characterized by very large occult precipitation [3]. Argan tree is a thermophilic and
xerophytic tree species, evolving in warm temperate arid bioclimate (along the coast and in
the plains) and in warm temperate semiarid bioclimate (High Atlas and Anti-Atlas), with
annual rainfall ranging from 400 mm in the north (Safi), 250 mm in the Souss Valley, and
150 mm in the Anti-Atlas to less than 100 mm in the southern areas of desert nature [4].
This tree, which can live up to 250 years [5], provides multiple uses for the local population:
its very hard wood and the shell of the fruit are used for heating, the leaves and the pulp of its
fruit and the oil cake are a valuable fodder for the flock, its thorny branches are used as fence
for agricultural plots, edible oil and cosmetics are derived from its seed, and finally the rich
soil of the forest area is a very favorable area for intercropping.
During recent years, the argan tree faces many constraints that result in the weakening and
degradation of natural forest ecosystems. The argan forests face, in recent decades, the
changes in climate and many anthropozoogenic disturbances that result in a reduction in area
and density and inexorably lead to the weakening and deterioration of the natural forest
ecosystems. As part of the global forest resources assessment [6], official figures provided by
Morocco and relating to the degradation of the argan tree show a decrease of 111 km2 of the
total area of the argan tree between 1990 and 2005, which corresponds to a decrease of
7.4 km2/year. On the other hand, the argan forests are in almost total lack of natural
regeneration [7].